|Print Page Close Window|
Stockholder OverviewCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ...
NASDAQ CRVS (Common Stock)
$12.39 - 0.2 (1.59%)
08/17/174:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference08/11/17
Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update08/03/17
Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology07/06/17
There are currently no events scheduled.